Sagimet Biosciences (SGMT) Operating Leases (2022)
Sagimet Biosciences' (SGMT) quarterly Operating Leases came in at $78000.0 in Q4 2022.
Sagimet Biosciences (SGMT) Operating Leases (2022) Analysis & Trends
Sagimet Biosciences' Operating Leases history runs 1 years deep, the most recent figure standing at $78000.0 for Q4 2022.
- On a quarterly basis, Operating Leases changed N/A year-over-year to $78000.0 in Q4 2022; TTM through Dec 2022 was $78000.0, a N/A change from a year earlier, with the FY2022 full-year figure at $78000.0, changed N/A from the prior year.
- Operating Leases steadied at $78000.0 in Q4 2022 per SGMT's latest filing.
- Across five years, Operating Leases topped out at $78000.0 in Q4 2022 and bottomed at $78000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Sagimet Biosciences | 227.27 Mn | 227.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 78,000.00 |